JP2009536188A - 抗ウイルス性ピリミジンヌクレオシド誘導体 - Google Patents
抗ウイルス性ピリミジンヌクレオシド誘導体 Download PDFInfo
- Publication number
- JP2009536188A JP2009536188A JP2009508479A JP2009508479A JP2009536188A JP 2009536188 A JP2009536188 A JP 2009536188A JP 2009508479 A JP2009508479 A JP 2009508479A JP 2009508479 A JP2009508479 A JP 2009508479A JP 2009536188 A JP2009536188 A JP 2009536188A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- valine
- compound according
- formula
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000840 anti-viral effect Effects 0.000 title description 6
- 150000003833 nucleoside derivatives Chemical class 0.000 title description 4
- 239000002718 pyrimidine nucleoside Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 46
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 12
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 12
- 208000036142 Viral infection Diseases 0.000 claims abstract description 11
- 150000001413 amino acids Chemical group 0.000 claims abstract description 11
- 230000009385 viral infection Effects 0.000 claims abstract description 11
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 8
- 230000007935 neutral effect Effects 0.000 claims abstract description 8
- 239000004474 valine Substances 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims abstract description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000004279 alanine Nutrition 0.000 claims abstract description 3
- 229960000310 isoleucine Drugs 0.000 claims abstract description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims abstract description 3
- 229940125898 compound 5 Drugs 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 12
- 229940024606 amino acid Drugs 0.000 claims description 9
- 235000001014 amino acid Nutrition 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 8
- 229960004295 valine Drugs 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- -1 n- pentyl Chemical group 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 238000005886 esterification reaction Methods 0.000 claims description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims description 2
- 229930182831 D-valine Natural products 0.000 claims description 2
- 229960003767 alanine Drugs 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 230000032050 esterification Effects 0.000 claims description 2
- 229960003136 leucine Drugs 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 229940126214 compound 3 Drugs 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 abstract description 10
- 201000006082 Chickenpox Diseases 0.000 abstract description 3
- 208000007514 Herpes zoster Diseases 0.000 abstract description 3
- 206010046980 Varicella Diseases 0.000 abstract description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 150000002367 halogens Chemical class 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 150000003680 valines Chemical class 0.000 description 2
- VJLYHTOSFSGXGH-CQSZACIVSA-N (2R)-1-[3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxybenzoyl]pyrrolidine-2-carboxylic acid Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)N2[C@H](CCC2)C(=O)O)C=CC=1 VJLYHTOSFSGXGH-CQSZACIVSA-N 0.000 description 1
- UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- QRTADFOPPOKFDH-UHFFFAOYSA-N 20,21-dihydroxyhenicosanoic acid Chemical compound OCC(O)CCCCCCCCCCCCCCCCCCC(O)=O QRTADFOPPOKFDH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 238000003436 Schotten-Baumann reaction Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001356 alkyl thiols Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 150000001504 aryl thiols Chemical class 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
上記一般式(II)[式中、Xは、O、S、NH、またはCH2であり;Yは、O、S、またはNHであり;Zは、O、S、またはCH2であり;R1は、C1〜6アルキルであり、n−ペンチルまたはn−ヘキシルを含むn−アルキルが好ましく;R2およびR3の1つはOHであり、そしてR3およびR2の他方は中性で非極性のアミノ酸分子である]で示される化合物、またはその医薬的に許容し得る塩もしくは水和物を提供する。該中性で非極性のアミノ酸分子のR2またはR3は、上記式(IV)[式中、R4、R5、R6およびR7は各々独立してHまたはC1〜2アルキルである]であり得る。特に好ましい実施態様において、R2またはR3の1つはバリン、ロイシン、イソロイシン、またはアラニンであり、バリンが特に好ましい。
Description
Aは、置換されていてもよい芳香族環式であり、該芳香族環式は1つの6員芳香環または2つの縮合6員芳香環を含み;
R8およびR9は各々独立して、水素、アルキル、シクロアルキル、ハロゲン、アミノ、アルキルアミノ、ジアルキルアミノ、ニトロ、シアノ、アルキルオキシ、アリールオキシ、チオール、アルキルチオール、アリールチオール、およびアリールからなる群から選ばれ;
Qは、O、S、およびCY2からなる群から選ばれ、ここで、Yは同じかまたは異なり、そしてH、アルキル、またはハロゲンから選ばれ;
Xは、O、NH、S、N−アルキル、(CH2)(ここで、mは1〜10である)、およびCY2(ここで、Yは同じかまたは異なり、そして水素、アルキル、またはハロゲンから選ばれる)からなる群から選ばれ;
Zは、O、S、NH、およびN−アルキルからなる群から選ばれ;
U’’はHであり、そしてU’はHまたはCH2Tから選ばれるか、あるいはU’およびU’’は一緒になってQを含有する環分子を形成し、ここで、U’−U’’は一緒になってそれぞれ、CTH−CT’T’’およびCT’=CT’からなる群から選ばれて、式:
Tは、OH、H、ハロゲン、O−アルキル、O−アシル、O−アリール、CN、NH2、およびN3からなる群から選ばれ;
T’は、Hおよびハロゲンからなる群から選ばれ、ここで、1個より多いT’が存在する場合には、それらは同じかまたは異なってもよく;
T’’は、Hおよびハロゲンからなる群から選ばれ;そして、
Wは、H、ホスフェート基、その薬理学的に許容し得る塩、誘導体およびプロドラッグからなる群から選ばれ;
但し、TがOAcである場合には、T’およびT’’は存在しそしてHであり、Arは4−(2−ベンゾキサゾリル)フェニルではない]
からなる群から選ばれる環分子を提供する。
Xは、O、S、NH、またはCH2であり;
Yは、O、S、またはNHであり;
Zは、O、S、またはCH2であり;
R1は、C1〜6アルキル、n−ペンチルまたはn−ヘキシルを含むn−アルキルが好ましく;そして、
R2およびR3の1つはOHであり、そしてR3およびR2の他方は中性で非極性のアミノ酸分子である]
の化合物、またはその医薬的に許容し得る塩もしくは水和物を提供する。
化合物の製造
実施例1
化合物5の製造;バリンエステルの生成
1H-NMR (CDCl3) δ: 8.3 (1H, s), 7.55 (2H, d), 7.15 (2H, d), 6.6 (1H, s), 6.25 (1H, t), 4.45-4.30 (4H, m), 3.23 (1H, d), 2.80 (1H, m), 2.53 (2H, t), 2.12 (1H, m), 1.97 (1H, m), 1.60 (2H, m), 1.24 (4H, m), 0.90-0.78 (9H, m)。
13C-NMR (CDCl3) δ: 175.16, 171.62,156.26, 154.89, 145.19, 135.29, 129.02, 125.69, 124.95, 108.60, 96.82, 88.73, 85.08, 70.90, 64.19, 60.19, 41.91, 35.82, 32.32, 31.44, 30.89, 22.50, 19.30, 17.24, 13.99。
化合物6の製造;HCl塩の生成
1H-NMR (d6-DMSO) δ: 8.6 (4H, bs), 7.70 (2H, d), 7.30 (2H, d), 7.20 (1H, s), 6.22 (1H, t), 5.60 (1H, bs), 4.48 (2H, m), 4.30 (1H, m), 4.16 (1H, m), 3.98 (1H, m), 2.61 (2H, t), 2.44 (1H, m), 2.25 (1H, m), 2.18 (1H, m), 1.57 (2H, m), 1.32 (4H, m), 1.00-0.83 (9H, m)。
13C-NMR (d6-DMSO) δ: 171.13, 168.88, 153.97, 153.70, 144.18, 137.94, 129.04, 125.77, 124.58, 107.22, 98.75, 87.71, 84.13, 69.73, 65.26, 57.35, 40.18, 34.88, 30.88, 30.39, 29.38, 21.91, 18.26, 17.55, 13.90。
化合物5の改善された曝露プロファイルを実証するために、いくつかの実験をマウス動物モデルを用いて行なった。以下に、代表的な結果を挙げる。
このパイロット研究の目的は、チミジン−キナーゼ欠損Oka VZV菌株を接種されたHEL細胞中の化合物1および化合物5の抗ウイルス活性を比較することであった。抗ウイルス活性を、未処置のコントロール培養物と比較した、3〜7日の間に及ぶインキュベート期間後のウイルスのプラーク形成を減少させる、化合物1または化合物5の能力として評価した。2つの化合物の間の匹敵する効力を示す抗ウイルス効力の研究の予備的な結果を表4.2に示す。
パイロット研究は化合物1および化合物5を用いて行なって、マウスにおける経口投与後の化合物1の相対的なバイオアベイラビリティを比較した。雌性マウスの2群は、0.5%カルボキシメチルセルロース中に製剤化された1回強制経口投与として、化合物1(25mg/kg)または化合物5(31.25mg/kg;化合物1の25mg/kgに相当)の当モル用量を与えた。該マウスは連続的に、投与後の0.25〜3時間の範囲の時点で殺され(3マウス/時点)、そして血漿標本を採取し、蛍光検出を伴うノンバリデート(non-validated)HPLC方法を用いて、化合物1の濃度について分析した。結果は化合物1についての相対ピーク面積として報告し、ここで、ピーク面積はこれらの濃度の範囲にわたって濃度に正比例すると仮定する。
Claims (19)
- R6およびR7は共にHである、請求項2記載の化合物。
- R2およびR3の1つはバリン、ロイシン、イソロイシン、またはアラニンである、請求項1記載の化合物。
- R2またはR3はバリンである、請求項1または請求項4のいずれかに記載の化合物。
- バリンはL−バリン、D−バリン、またはD,L−バリンである、請求項5記載の化合物。
- X、YおよびZは好ましくは全てOである、請求項1〜6のいずれか1つに記載の化合物。
- R6およびR7は共にHであり、そして該α−アミノ基は、3,9−フルオレニルメトキシカルボニル(Fmoc)保護基によってエステル化反応の間に保護される、請求項11記載の方法。
- エステル化はミツノブ条件下で行なう、請求項10〜12のいずれか1つに記載の方法。
- 更に、エステルをHClの溶液を用いて処理して塩酸塩を得ることを含む、請求項10〜13のいずれか1つに記載の方法。
- R1はn−ペンチルまたはn−ヘキシルであり、X、YおよびZは全てOであり、そしてR4およびR5は共にメチルである、請求項10〜14のいずれか1つに記載の方法。
- ヒトまたは動物の身体の処置方法における使用のための、請求項1〜9のいずれか1つに記載の化合物。
- ウイルス感染症の予防または治療のための医薬の製造における、請求項1〜9のいずれか1つに記載の化合物の使用。
- 処置が必要なヒトまたは非ヒト動物の患者に請求項1〜9のいずれか1つに記載の化合物の有効量を投与することを含む、ウイルス感染症の予防または治療のための方法。
- 請求項1〜9のいずれか1つに記載の化合物を医薬的に許容し得る賦形剤と組み合わせて含有する、医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0609178.9A GB0609178D0 (en) | 2006-05-09 | 2006-05-09 | Novel compounds |
GB0609178.9 | 2006-05-09 | ||
PCT/GB2007/001677 WO2007129083A1 (en) | 2006-05-09 | 2007-05-09 | Anti-viral pyrimidine nucleoside derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009536188A true JP2009536188A (ja) | 2009-10-08 |
JP2009536188A5 JP2009536188A5 (ja) | 2011-01-13 |
JP5261374B2 JP5261374B2 (ja) | 2013-08-14 |
Family
ID=36637171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009508479A Expired - Fee Related JP5261374B2 (ja) | 2006-05-09 | 2007-05-09 | 抗ウイルス性ピリミジンヌクレオシド誘導体 |
Country Status (22)
Country | Link |
---|---|
US (3) | US8329664B2 (ja) |
EP (1) | EP2016081B1 (ja) |
JP (1) | JP5261374B2 (ja) |
KR (1) | KR101447522B1 (ja) |
CN (1) | CN101443332B (ja) |
AT (1) | ATE506367T1 (ja) |
AU (1) | AU2007246814B2 (ja) |
BR (1) | BRPI0711354A2 (ja) |
CA (1) | CA2656780C (ja) |
CY (1) | CY1111711T1 (ja) |
DE (1) | DE602007014030D1 (ja) |
DK (1) | DK2016081T3 (ja) |
EA (1) | EA015178B1 (ja) |
ES (1) | ES2365057T3 (ja) |
GB (1) | GB0609178D0 (ja) |
IL (1) | IL194806A (ja) |
NZ (1) | NZ573377A (ja) |
PL (1) | PL2016081T3 (ja) |
PT (1) | PT2016081E (ja) |
SI (1) | SI2016081T1 (ja) |
TW (1) | TWI385172B (ja) |
WO (1) | WO2007129083A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013539760A (ja) * | 2010-10-09 | 2013-10-28 | シナジー ファーマシューティカルズ インコーポレイテッド | 抗ウイルス化合物およびその有用な中間体の調製方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0009486D0 (en) * | 2000-04-17 | 2000-06-07 | Univ Cardiff | Chemical compounds |
GB2452556A (en) * | 2007-09-07 | 2009-03-11 | Univ Leuven Kath | Nucleoside analogues esterified at 3 and/or 5 positions by neutral non-polar amino acid, or oligopeptide thereof, for combating Varicella Zoster virus |
CN102443032B (zh) * | 2010-10-09 | 2015-07-22 | 英希比泰克斯公司 | 制备抗病毒组合物的方法及其中间体的应用 |
MD4110C1 (ro) * | 2010-10-21 | 2011-12-31 | Валериу РУДИК | Preparat antiherpetiс |
KR101875997B1 (ko) * | 2015-05-04 | 2018-07-06 | 엔 앤드 엔 파마세우티칼스 인크. | 엔-메탄노카르바티미딘을 이용한 대상포진의 치료방법 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001504468A (ja) * | 1996-11-15 | 2001-04-03 | エール・ユニヴァーシティ | L―β―ジオキソランウリジン類似体及びウイルス感染の治療とその予防方法 |
JP2003532735A (ja) * | 2000-05-09 | 2003-11-05 | ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド | 抗ウイルスピリミジンヌクレオシド類 |
JP2004506606A (ja) * | 2000-04-17 | 2004-03-04 | ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド | 抗ウイルスピリミジンヌクレオシド類 |
JP2004533403A (ja) * | 2000-06-15 | 2004-11-04 | イデニクス(ケイマン)リミテツド | 2’−デオキシ−β−L−ヌクレオシドの3’−プロドラッグ |
US20040266996A1 (en) * | 2003-03-20 | 2004-12-30 | Rabi Jaime A | Methods of manufacture of 2'-deoxy-beta-L-nucleosides |
US20050137141A1 (en) * | 2003-10-24 | 2005-06-23 | John Hilfinger | Prodrug composition |
JP2005533817A (ja) * | 2002-06-28 | 2005-11-10 | イデニクス(ケイマン)リミテツド | フラビウィルス科ウィルス感染治療用の修飾2′および3′−ヌクレオシドプロドラッグ |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62255499A (ja) | 1986-04-28 | 1987-11-07 | Teijin Ltd | 螢光性ヌクレオシド又はヌクレオチド |
EP0346108A3 (en) | 1988-06-09 | 1991-04-24 | The Wellcome Foundation Limited | Anti-infective nucleosides |
YU43193A (sh) | 1992-06-22 | 1997-01-08 | Eli Lilly And Company | 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi |
GB9505025D0 (en) | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
GB9708611D0 (en) | 1997-04-28 | 1997-06-18 | Univ Cardiff | Chemical compounds |
GB9716231D0 (en) | 1997-07-31 | 1997-10-08 | Amersham Int Ltd | Base analogues |
CA2379988C (en) | 1999-07-22 | 2010-10-19 | Newbiotics, Inc. | Enzyme catalyzed therapeutic activation |
AU6358900A (en) | 1999-07-22 | 2001-02-13 | Newbiotics, Inc. | Enzyme catalyzed anti-infective therapeutic agents |
CN1391486A (zh) | 1999-07-22 | 2003-01-15 | 新生物公司 | 治疗对治疗有抗性的肿瘤的方法 |
US6875751B2 (en) * | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
WO2005121162A1 (en) | 2004-06-07 | 2005-12-22 | Anadys Pharmaceuticals, Inc. | 3-β-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF |
-
2006
- 2006-05-09 GB GBGB0609178.9A patent/GB0609178D0/en not_active Ceased
-
2007
- 2007-05-09 JP JP2009508479A patent/JP5261374B2/ja not_active Expired - Fee Related
- 2007-05-09 AU AU2007246814A patent/AU2007246814B2/en not_active Ceased
- 2007-05-09 KR KR1020087029280A patent/KR101447522B1/ko not_active IP Right Cessation
- 2007-05-09 CN CN2007800169982A patent/CN101443332B/zh not_active Expired - Fee Related
- 2007-05-09 US US12/226,044 patent/US8329664B2/en not_active Expired - Fee Related
- 2007-05-09 DK DK07732706.2T patent/DK2016081T3/da active
- 2007-05-09 ES ES07732706T patent/ES2365057T3/es active Active
- 2007-05-09 PT PT07732706T patent/PT2016081E/pt unknown
- 2007-05-09 AT AT07732706T patent/ATE506367T1/de active
- 2007-05-09 BR BRPI0711354-4A patent/BRPI0711354A2/pt not_active IP Right Cessation
- 2007-05-09 SI SI200730661T patent/SI2016081T1/sl unknown
- 2007-05-09 EP EP07732706A patent/EP2016081B1/en not_active Not-in-force
- 2007-05-09 CA CA 2656780 patent/CA2656780C/en not_active Expired - Fee Related
- 2007-05-09 DE DE602007014030T patent/DE602007014030D1/de active Active
- 2007-05-09 PL PL07732706T patent/PL2016081T3/pl unknown
- 2007-05-09 NZ NZ573377A patent/NZ573377A/en not_active IP Right Cessation
- 2007-05-09 WO PCT/GB2007/001677 patent/WO2007129083A1/en active Application Filing
- 2007-05-09 TW TW096116477A patent/TWI385172B/zh not_active IP Right Cessation
- 2007-05-09 EA EA200870505A patent/EA015178B1/ru not_active IP Right Cessation
-
2008
- 2008-10-22 IL IL194806A patent/IL194806A/en active IP Right Grant
-
2011
- 2011-07-15 CY CY20111100693T patent/CY1111711T1/el unknown
-
2012
- 2012-11-30 US US13/690,794 patent/US8859512B2/en not_active Expired - Fee Related
-
2014
- 2014-09-10 US US14/482,125 patent/US9427447B2/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001504468A (ja) * | 1996-11-15 | 2001-04-03 | エール・ユニヴァーシティ | L―β―ジオキソランウリジン類似体及びウイルス感染の治療とその予防方法 |
JP2004506606A (ja) * | 2000-04-17 | 2004-03-04 | ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド | 抗ウイルスピリミジンヌクレオシド類 |
JP2003532735A (ja) * | 2000-05-09 | 2003-11-05 | ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド | 抗ウイルスピリミジンヌクレオシド類 |
JP2004533403A (ja) * | 2000-06-15 | 2004-11-04 | イデニクス(ケイマン)リミテツド | 2’−デオキシ−β−L−ヌクレオシドの3’−プロドラッグ |
JP2005533817A (ja) * | 2002-06-28 | 2005-11-10 | イデニクス(ケイマン)リミテツド | フラビウィルス科ウィルス感染治療用の修飾2′および3′−ヌクレオシドプロドラッグ |
US20040266996A1 (en) * | 2003-03-20 | 2004-12-30 | Rabi Jaime A | Methods of manufacture of 2'-deoxy-beta-L-nucleosides |
US20050137141A1 (en) * | 2003-10-24 | 2005-06-23 | John Hilfinger | Prodrug composition |
Non-Patent Citations (2)
Title |
---|
JPN6012043890; Christopher McGuigan et al.: Bioorganic & Medicinal Chemistry Letters Vol.6(10), 1996, p.1183-1186 * |
JPN6012043891; Annette Angell et al.: Bioorganic & Medicinal Chemistry Letters Vol.14, 2004, p.2397-2399 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013539760A (ja) * | 2010-10-09 | 2013-10-28 | シナジー ファーマシューティカルズ インコーポレイテッド | 抗ウイルス化合物およびその有用な中間体の調製方法 |
JP2016172755A (ja) * | 2010-10-09 | 2016-09-29 | コントラヴィア・ファーマシューティカルズ・インコーポレイテッドContraVir Pharmaceuticals, Inc. | 抗ウイルス化合物およびその有用な中間体の調製方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4923216B2 (ja) | 化合物 | |
KR101612642B1 (ko) | 테노포비어 알라펜아미드 헤미푸마레이트 | |
US9427447B2 (en) | Anti-viral pyrimidine nucleoside derivatives | |
JP2002525374A (ja) | 抗ウイルスプリン誘導体 | |
JP2004506606A (ja) | 抗ウイルスピリミジンヌクレオシド類 | |
IL228220A (en) | Tricyclic inhibitors of the gyrase enzyme | |
WO2009005693A1 (en) | Novel hiv reverse transcriptase inhibitors | |
ITMI951450A1 (it) | Esteri acilici di amminoacidi achirali di gangiclovir e relativi derivati | |
EP1123935B1 (en) | 3'-Fluorinated guanosine derivatives for the treatment or prophylaxis of HBV or retroviral infections | |
JPWO2006082821A1 (ja) | ヘルペスウイルスが関与する疾患の予防若しくは治療剤 | |
ES2357768T3 (es) | Ácidos 2-(3-fenil-2-piperazinil-2,4-dihidroquinazolin-4-il)-acéticos como agentes antivirales, especialmente contra citomegalovirus. | |
TW200927147A (en) | Improvements in or relating to compositions for the treatment or prophylaxis of viral infections | |
US20170114087A1 (en) | Method of preparation of antiviral compounds and useful intermediates thereof | |
US8349834B2 (en) | Dioxolane derivates for the treatment of cancer | |
ES2829254T3 (es) | Nucleósidos de pirrolopirimidina y análogos de los mismos útiles como agentes antivíricos | |
WO2023230472A1 (en) | Inhibitors of molluscum contagiosum infection and methods using the same | |
JPH05194518A (ja) | 6−メルカプトプリン誘導体及びその製法 | |
KR20000051515A (ko) | 항바이러스 활성을 가지는 2-아미노퓨린 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100415 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100415 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101115 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120821 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121120 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121220 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130402 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130426 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160502 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |